Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DYNAVAX TECHNOLOGIES CORP Director's Dealing 2023

May 31, 2023

32130_dirs_2023-05-31_de7c4b89-8069-4107-9c42-6e0cd2fc89cc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DYNAVAX TECHNOLOGIES CORP (DVAX)
CIK: 0001029142
Period of Report: 2023-05-26

Reporting Person: Hack Andrew A. F. (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-26 Common Stock A 5357 $0.00 Acquired 10714 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-05-26 Stock Option (Right to Buy) $11.20 A 22500 Acquired 2030-05-25 Common Stock (22500) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2915000 Indirect

Footnotes

F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company.

F2: The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes 5,357 newly awarded RSUs and 5,357 RSUs previously reported in Table II.

F3: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date.

F4: Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

F5: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.